Gilead Sciences has reported strong second-quarter 2026 results, with total revenue increasing by 10% year-on-year to $7.8bn, driven by continued growth across its HIV portfolio, oncology medicine Trodelvy and liver disease therapy Livdelzi, despite continued market headwinds. HIV portfolio fuels growthHIV product sales rose 12% to $5.7bn, reflecting sustained demand for treatment medicines alongside the rapid expansion of the company’s pre-exposure prophylaxis (PrEP) business. Excluding these one-time costs, the company said its underlying business continued to perform strongly across its key therapeutic areas. The company also highlighted progress across its development pipeline, with ongoing investment in programmes spanning HIV, oncology, liver disease and inflammation. 2026 outlook raisedBased on the quarter’s performance, Gilead increased its 2026 outlook, raising expectations for HIV sales growth and modestly increasing full-year product sales guidance.